KRAS and neoplasm: Utilizing albumin as a drug carrier, it enters KRAS‐mutant malignant cells via macropinocytosis and reprograms tumor metabolism through covalently conjugated biguanides (inhibiting glycolysis) and flavonoids (suppressing glutaminolysis), inducing synthetic lethality while reducing tumor fibrosis and immunosuppression.[53]